Want to see ATRC full AI Analyst Report?
ATRC Stock Chart & Stats
$29.72
$0.79(2.42%)
At close: 4:00 PM EST
$29.72
$0.79(2.42%)
Day’s Range― - ―
52-Week Range$25.36 - $43.18
Previous CloseN/A
Volume180.64K
Average Volume (3M)926.84K
Market Cap
$1.77B
Enterprise Value$1.33K
Total Cash (Recent Filing)$146.16M
Total Debt (Recent Filing)$74.91M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Jul 23, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding50,640,970
10 Day Avg. Volume752,839
30 Day Avg. Volume926,839
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)3.84
Price to Sales (P/S)3.53
P/FCF Ratio39.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$49.00Price Target Upside64.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.04
Revenue Forecast (FY)$604.96M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & Product AdoptionMulti-year revenue scaling demonstrates durable demand and expanding clinical adoption across franchises. Sustained top-line growth reflects broader procedure penetration and successful new-product uptake that should support ongoing revenue expansion over the next several quarters.
High And Stable Gross MarginsA consistently high gross margin base reflects favorable product mix and pricing power in surgical ablation and appendage devices. Durable margins provide cushion for incremental R&D and SG&A, enabling reinvestment while protecting operating profitability as volumes grow.
Strengthening Cash Generation & Low LeverageMaterial improvement in operating and free cash flow combined with modest debt (declining to ~$72M) yields financial flexibility. Positive cash generation supports R&D, trial funding and manufacturing investment without relying heavily on external capital over the medium term.
Bears Say
Inconsistent GAAP ProfitabilityWhile margins and adjusted metrics improved, GAAP profitability remains inconsistent. Continued negative net income limits return generation on the equity base and could pressure reserves or capital allocation if operational improvements stall or clinical investments rise.
MIS Ablation Volume DeclinesA steep decline in minimally invasive ablation volumes signals procedural adoption headwinds in a sub-franchise. Persistent weakness here can constrain overall growth and reduce cross-sell opportunities, particularly if clinicians shift to alternative therapies or delay referrals.
International & Near-Term Expense/Manufacturing PressureDistributor lumpiness and regional softness create revenue variability outside the U.S., while elevated R&D/SG&A and a manufacturing ramp will increase near-term cost pressure. Together these factors could moderate margin expansion and amplify execution risk during the scaling period.
Atricure News
ATRC FAQ
What was Atricure, Inc.’s price range in the past 12 months?
Atricure, Inc. lowest stock price was $25.36 and its highest was $43.18 in the past 12 months.
What is Atricure, Inc.’s market cap?
Atricure, Inc.’s market cap is $1.77B.
When is Atricure, Inc.’s upcoming earnings report date?
Atricure, Inc.’s upcoming earnings report date is Jul 23, 2026 which is in 2 days.
How were Atricure, Inc.’s earnings last quarter?
Atricure, Inc. released its earnings results on May 05, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.059 by $0.059.
Is Atricure, Inc. overvalued?
According to Wall Street analysts Atricure, Inc.’s price is currently Undervalued.
Does Atricure, Inc. pay dividends?
Atricure, Inc. does not currently pay dividends.
What is Atricure, Inc.’s EPS estimate?
Atricure, Inc.’s EPS estimate is >-0.01.
How many shares outstanding does Atricure, Inc. have?
Atricure, Inc. has 50,640,970 shares outstanding.
What happened to Atricure, Inc.’s price movement after its last earnings report?
Atricure, Inc. reported an EPS of $0 in its last earnings report, beating expectations of -$0.059. Following the earnings report the stock price went down -4.695%.
Which hedge fund is a major shareholder of Atricure, Inc.?
Currently, no hedge funds are holding shares in ATRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atricure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (64.87% Upside)
$49.00 (64.87% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 142.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $226.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.9%
Last 30 Days ▲ 18.9%
Last 30 Days ▲ 18.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.85%
Trailing 12-Months
Company Description
Atricure, Inc.
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
ATRC Stock 12 Month Forecast
Average Price Target
$49.00
▲(64.87% Upside)
Technical Analysis
Ownership Overview
4.04% Insiders
42.71% Mutual Funds
0.80% Other Institutional Investors
35.11% Public Companies and
Individual Investors